Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. The company offers ImmunoINSIGHTS platform, an autoantibody profiling service that provides insights to discover and validate novel biomarkers, validate drug mode of action, improve treatment responses and adverse event (irAE) prediction, patient screening, and diagnostic accuracy; Sero Tag, a discovery engine for the identification of relevant biomarker pool for target discovery or companion diagnostics; NavigAID for creation of a disease-specific biomarker panel; and Autoantibody Biomarkers, a companion diagnostic biomarker. It also provides business development and marketing services. Oncimmune Holdings plc was incorporated in 2015 and is headquartered in Leeds, the United Kingdom.
Frequently asked questions
What sector does ONCIMMUNE HLDNGS LS-01 (OCY) operate in?
ONCIMMUNE HLDNGS LS-01 belongs to the Other sector and operates in the Biotechnology industry.
What is ONCIMMUNE HLDNGS LS-01 (OCY) current stock price?
As of the latest data, ONCIMMUNE HLDNGS LS-01 stock price is €0.01, with a previous close of €0.01.
What is ONCIMMUNE HLDNGS LS-01 (OCY) current market capitalization?
ONCIMMUNE HLDNGS LS-01 market cap is approximately 1.23 million.
What is ONCIMMUNE HLDNGS LS-01 (OCY) Earnings Per Share (EPS)?
The trailing EPS is -€0.06.
Does ONCIMMUNE HLDNGS LS-01 (OCY) pay dividends?
No. ONCIMMUNE HLDNGS LS-01 does not pay a dividend.
What is ONCIMMUNE HLDNGS LS-01 (OCY) beta (volatility) score?
ONCIMMUNE HLDNGS LS-01 has a beta of 1.599, suggesting it is more volatile than the market.
